Natera, a genetic testing company known for its cancer detection products, delivered a third-quarter revenue beat and lifted its 2026 outlook. But instead of celebrating, investors sent the stock down nearly 16% in a single session. The sharp drop highlights a key truth about high-growth stocks: beating sales estimates is often not enough when the market is more focused on when profits will finally arrive.
What happened
Natera reported third-quarter revenue that came in ahead of Wall Street's expectations, and management raised its revenue guidance for 2026. That sounds like good news on the surface. Yet the stock fell 15.69% to $306.70, a move that suggests investors were looking past the headline numbers.
The reason for the pessimism appears to be the company's path to profitability. While revenue is growing, Natera is also spending heavily on research and development, and launching new products that are putting short-term pressure on gross margins. RBC Capital Markets, an investment bank, noted that the company's 2027 operating expense expectations have been raised, partly due to more R&D spending, while gross margin assumptions were trimmed because of new product launches.
For investors, this means the moment when Natera shows operating leverage—when profit growth outpaces revenue growth—may be further away than previously hoped. Operating leverage is a key metric for growth stocks because it signals that a company can scale without costs growing at the same pace. When that timeline gets pushed out, the stock often reprices sharply, even on a solid quarter.
The MRD story remains intact
Despite the selloff, RBC remains bullish on Natera's core story: minimal residual disease (MRD) testing. MRD testing looks for tiny traces of cancer DNA in a patient's blood after treatment, helping doctors detect recurrence earlier than traditional scans. Natera's flagship product in this space is Signatera, which RBC believes is a leading offering.
The bank points to a large runway for growth, citing management's ambition to reach $6 billion in revenue by 2029 and an estimated market opportunity above $15 billion. That's a big prize, and Natera is positioning itself to capture a significant share.
There are also signs of improving pricing power. Signatera's average selling price rose to about $1,290 in the third quarter, up from $1,271 in the second quarter. That may not sound like a huge jump, but it hints that Natera is able to charge more as volumes scale, either through better product mix or stronger negotiating position with payers.
CEO transition adds uncertainty
Adding to the market's jitters was the announcement that CEO Steve Chapman is stepping down after nearly eight years at the helm. Solomon Moshkevich is set to take over. Leadership changes at high-growth companies can create uncertainty, as investors wonder whether the new CEO will maintain the same strategic direction and execution pace.
RBC, however, seems to view the transition as manageable, sticking with its $460 price target even after the stock's sharp decline. That implies the bank sees the selloff as overdone, at least relative to its own valuation model.
What it means for investors
For everyday investors, this episode is a useful reminder that with expensive growth stocks, the debate is rarely just about whether revenue beat expectations. The market is constantly trying to model the "profit algorithm": how quickly gross margins rise, and whether operating costs stop growing faster than sales.
When a company like Natera raises its outlook but also signals higher spending and near-term margin pressure, the market can react negatively because the payoff seems further away. That's why a stock can fall sharply even on what looks like a solid quarter.
It also explains why execution signals, like a CEO transition, can keep shares jumpy until the path to margin expansion feels clearer. Investors will likely be watching for signs that Natera's new leadership can balance growth with cost discipline, and that the margin pressure from product launches is temporary.
For those holding Natera or considering it, the key question is whether you believe the long-term MRD opportunity justifies the near-term uncertainty. That's a judgment call, not a recommendation. But understanding why the stock moved—and what metrics matter—can help you make more informed decisions.
In the broader context, Natera's situation echoes other growth stories where raising an outlook doesn't always translate into a higher stock price if the market is worried about the cost of getting there. Similarly, Moderna's recent guidance boost was met with a more positive reaction, but that company's profitability profile is different. Each story is unique, but the underlying tension between growth and profitability is a common theme.
As always, it's wise to look beyond the headline numbers and consider the full picture, including management changes, spending plans, and margin trends. That's how you can better understand why a stock moves the way it does.
